XOMA Royalty to acquire LAVA Therapeutics for $32.6m.

XOMA Royalty, a biotechnology royalty aggregator, agreed to acquire LAVA Therapeutics, a biopharmaceutical company, for $32.6m. “We believe the structure of this transaction has the potential to benefit both LAVA and XOMA Royalty shareholders over time. We are adding economics related to LAVA’s partnered programs investigating the utility of gamma delta bispecific antibodies, which hold significant promise for patients,” Owen Hughes, XOMA Royalty CEO.